- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | City Therapeutics auf der Stifel Healthcare Conference: Pipeline, Kapitalausstattung und Plattformtechnologie im Fokus | 2 | Investing.com Deutsch | ||
| Di | City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease | 1 | GlobeNewswire (USA) | ||
| Di | Goldman Sachs initiates City Therapeutics stock at Early-Stage Biotech | 1 | Investing.com | ||
| Di | CITY THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| Di | Stifel initiates City Therapeutics stock with buy on pipeline | 1 | Investing.com | ||
| Di | Jefferies initiates City Therapeutics stock with buy rating | 1 | Investing.com | ||
| Di | Jefferies nimmt City Therapeutics mit Kaufempfehlung und Kursziel von 32 Dollar auf | 3 | Investing.com Deutsch | ||
| 04.11. | City Therapeutics to present drug trial data at ASH meeting | 6 | Investing.com | ||
| CITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.11. | City Therapeutics: Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting | 8 | GlobeNewswire (USA) | ||
| 19.10. | CITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.10. | City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | 1 | GlobeNewswire (USA) | ||
| 17.10. | US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week's pricings | 4 | Renaissance Capital | ||
| 16.10. | CITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 16.10. | City Therapeutics' Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver | 1 | MedCity News | ||
| 16.10. | City Therapeutics glänzt beim Börsendebüt nach aufgestocktem $200-Millionen-Börsengang | 2 | Investing.com Deutsch | ||
| 16.10. | Börsengang von City Therapeutics: Hälfte der Zeichnungsaufträge geht laut Bericht leer aus | 3 | Investing.com Deutsch | ||
| 16.10. | City Therapeutics prices upsized IPO at $18, the midpoint of the range | 1 | Renaissance Capital | ||
| 16.10. | City Therapeutics prices upsized IPO at $18 per share | 2 | Investing.com | ||
| 16.10. | City Therapeutics Announces Pricing of Upsized Initial Public Offering | 2 | GlobeNewswire (USA) | ||
| 13.10. | CITY THERAPEUTICS, INC. - 8-A12B, Registration of securities | 1 | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
CITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 19,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CITY THERAPEUTICS INC finden Sie auf Wallstreet Online.